NON-SMALL CELL LUNG CANCER (NSCLC)
Clinical trials for NON-SMALL CELL LUNG CANCER (NSCLC) explained in plain language.
Never miss a new study
Get alerted when new NON-SMALL CELL LUNG CANCER (NSCLC) trials appear
Sign up with your email to follow new studies for NON-SMALL CELL LUNG CANCER (NSCLC), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug targets Hard-to-Treat cancers with RAS mutations
Disease control Recruiting nowThis study tests a new drug called RMC-6236 in adults with advanced solid tumors (like lung, colon, or pancreatic cancer) that have specific RAS gene mutations. The main goals are to check the drug's safety and find the right dose. About 754 people will take part, and the drug is…
Matched conditions: NON-SMALL CELL LUNG CANCER (NSCLC)
Phase: PHASE1, PHASE2 • Sponsor: Revolution Medicines, Inc. • Aim: Disease control
Last updated Apr 29, 2026 00:51 UTC
-
Could extra local treatment extend life in advanced lung cancer?
Disease control Recruiting nowThis study looks at people with stage IV non-small cell lung cancer whose tumors have spread. After initial standard therapy (chemo, immunotherapy, or targeted drugs), some will also get surgery or radiation on remaining tumors. The goal is to see if this extra local treatment he…
Matched conditions: NON-SMALL CELL LUNG CANCER (NSCLC)
Phase: NA • Sponsor: Swiss Cancer Institute • Aim: Disease control
Last updated Apr 29, 2026 00:51 UTC
-
New drug Rina-S shows promise in lung cancer trial
Disease control Recruiting nowThis study tests a new drug, Rina-S, in about 240 people with advanced non-small cell lung cancer that has worsened after other treatments. Everyone receives the active drug; no one gets a placebo. The goal is to see if Rina-S can shrink tumors and control the disease, with treat…
Matched conditions: NON-SMALL CELL LUNG CANCER (NSCLC)
Phase: PHASE2 • Sponsor: Genmab • Aim: Disease control
Last updated Apr 29, 2026 00:50 UTC
-
New pill aims to stop lung cancer relapse after surgery
Disease control Recruiting nowThis study tests whether the drug taletrectinib can prevent lung cancer from returning in people with a specific genetic marker (ROS1 fusion) after their tumor has been surgically removed. About 180 adults with stage IB to IIIA non-small cell lung cancer will receive either talet…
Matched conditions: NON-SMALL CELL LUNG CANCER (NSCLC)
Phase: PHASE3 • Sponsor: Nuvation Bio Inc. • Aim: Disease control
Last updated Apr 29, 2026 00:50 UTC
-
Could a leukemia drug tame resistant lung cancer?
Disease control Recruiting nowThis early-stage study tests gilteritinib, a drug already used for a type of leukemia, in people with ALK-positive non-small cell lung cancer whose cancer has stopped responding to standard ALK inhibitors. The main goal is to check the drug's safety and find the right dose. About…
Matched conditions: NON-SMALL CELL LUNG CANCER (NSCLC)
Phase: PHASE1 • Sponsor: Astellas Pharma Global Development, Inc. • Aim: Disease control
Last updated Apr 29, 2026 00:49 UTC
-
New drug candidate BMS-986463 enters first human trials for tough cancers
Disease control Recruiting nowThis early-phase study tests a new drug called BMS-986463 in people with advanced ovarian, uterine, or lung cancers that have not responded to other treatments. The main goals are to check safety and find the right dose. About 240 adults will take part, and researchers will also …
Matched conditions: NON-SMALL CELL LUNG CANCER (NSCLC)
Phase: PHASE1 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Apr 28, 2026 13:02 UTC
-
Glowing dye helps surgeons spot hidden lung cancer during operation
Diagnosis Recruiting nowThis study tests a special dye called LS301-IT that makes lung cancer cells glow during surgery. About 35 adults with early-stage lung cancer will receive the dye before their tumor-removal surgery. The goal is to help surgeons see cancer that is hard to spot with the naked eye, …
Matched conditions: NON-SMALL CELL LUNG CANCER (NSCLC)
Phase: PHASE2 • Sponsor: Integro Theranostics • Aim: Diagnosis
Last updated Apr 29, 2026 00:50 UTC
-
New imaging agent RAD301 tested for safety in cancer patients
Knowledge-focused Recruiting nowThis early-stage study tests a new substance called RAD301 in 9 people—some healthy, some with pancreatic, lung, esophageal, cervical, endometrial, or ovarian cancer. The goal is to see how RAD301 moves through the body and how much radiation reaches organs and tumors, and to che…
Matched conditions: NON-SMALL CELL LUNG CANCER (NSCLC)
Phase: PHASE1 • Sponsor: Radiopharm Theranostics, Ltd • Aim: Knowledge-focused
Last updated Apr 29, 2026 00:50 UTC